Monopar to Participate in the Maxim Group’s Healthcare Virtual Conference

WILMETTE, Ill., June 14, 2023 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that Chandler Robinson, MD, Monopar’s Chief Executive Officer, will participate in a one-on-one fireside chat with Jason McCarthy, PhD, Senior Managing Director of Equity Research, at the Maxim Group’s Healthcare Virtual Conference on Tuesday June 20, 2023 at 1:30pm ET.

Fireside Chat Details:
Date: June 20, 2023
Time: 1:30 pm ET
Location: Virtual Conference

About Monopar Therapeutics Inc.

Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients. Monopar’s pipeline consists of camsirubicin (Phase 1b) for the treatment of advanced soft tissue sarcoma; MNPR-101, a late-stage preclinical antibody for radiopharmaceutical use in advanced cancers; and MNPR-202, an early-stage camsirubicin analog for various cancers. For more information, visit: www.monopartx.com.

CONTACT:  

Monopar Therapeutics Inc.
Investor Relations  
Kim R. Tsuchimoto  
Chief Financial Officer  
kimtsu@monopartx.com

Follow Monopar on social media for updates: 
Twitter: @MonoparTx  LinkedIn: Monopar Therapeutics